Pheochromocytoma

Pathophysiology

• Pheochromocytomas are rare, catecholamine-secreting neuroendocrine tumors that arise from the chromaffin cells of the adrenal medulla.
• Paragangliomas are related extra-adrenal tumors that originate from sympathetic or parasympathetic paraganglia located throughout the autonomic nervous system.
• Approximately 10% of pheochromocytomas occur during childhood, typically presenting around a mean age of 13 years, with a slight male predominance in patients diagnosed before 10 years of age.
• While most pediatric pheochromocytomas secrete both epinephrine and norepinephrine (an adrenergic phenotype), tumors associated with certain hereditary syndromes or extra-adrenal paragangliomas may predominantly secrete norepinephrine (noradrenergic phenotype) or, rarely, dopamine.
• The clinical manifestations are a direct consequence of continuous or intermittent excessive catecholamine release, which induces profound systemic alpha- and beta-adrenergic receptor activation.

Clinical Features

Classic Symptoms

• Hypertension is a hallmark feature and is present in almost all affected children at some point.
• Unlike adults, who often experience paroxysmal blood pressure spikes, children typically present with sustained hypertension.
• The classic paroxysmal triad of severe headache, palpitations, and diaphoresis (sweating) can occur but is less common in pediatric patients compared to adults.
• Symptoms often occur during paroxysmal attacks triggered by physical exertion or medications, between which the patient may feel entirely asymptomatic.
• During an attack, patients frequently complain of pallor, dizziness, tremor, anxiety, and precordial pain that may radiate to the arms.

Nonspecific and Systemic Manifestations

• Children frequently exhibit a hypermetabolic state leading to severe weight loss or cachexia despite maintaining a good or even increased appetite.
• Visual disturbances, including blurred vision, papilledema, retinal hemorrhages, and arterial constriction on ophthalmoscopic examination, are common secondary to severe hypertension.
• Gastrointestinal manifestations include abdominal pain, nausea, vomiting, severe constipation, and occasionally intestinal pseudo-obstruction.
• Metabolic abnormalities such as hyperglycemia, along with polyuria and polydipsia that can be severe enough to mimic diabetes insipidus, are frequently observed.
• Neurological and behavioral changes include seizures, hypertensive encephalopathy, attention deficit hyperactivity disorder, and a sudden decline in academic performance.
• Bladder paragangliomas present uniquely with gross hematuria and paroxysmal hypertensive symptoms specifically triggered by micturition.
• Head and neck paragangliomas (parasympathetic) are typically non-secretory and present as a neck mass, hearing loss, pulsatile tinnitus, dysphagia, or hoarseness due to mass effect.

Complications

• Cardiovascular complications are a major source of morbidity and include takotsubo cardiomyopathy (catecholamine-induced cardiomyopathy), arrhythmias, pulmonary edema, and congestive heart failure.
• Severe hypertensive crises can lead to cerebrovascular accidents (stroke) or multisystem crisis and death if left unrecognized.

Genetic and Syndromic Associations

• Up to 80% of children with a pheochromocytoma or paraganglioma harbor a germline mutation, underscoring the vital importance of syndromic recognition.
• Multiple Endocrine Neoplasia Type 2 (MEN2A and MEN2B): Caused by RET proto-oncogene mutations, these patients develop pheochromocytomas (often bilateral and adrenergic) in association with medullary thyroid carcinoma and hyperparathyroidism (MEN2A) or mucosal neuromas and marfanoid habitus (MEN2B).
• Von Hippel-Lindau (VHL) Disease: Caused by VHL mutations, presenting with noradrenergic pheochromocytomas, retinal and central nervous system hemangioblastomas, and renal clear cell carcinomas.
• Neurofibromatosis Type 1 (NF1): Presents with adrenergic pheochromocytomas alongside café-au-lait spots, neurofibromas, optic gliomas, and Lisch nodules.
• Hereditary Paraganglioma-Pheochromocytoma Syndromes: Caused by mutations in the succinate dehydrogenase enzyme complex (SDHB, SDHD, SDHC, SDHA). SDHB mutations carry a notably high risk for extra-adrenal paragangliomas and malignant (metastatic) transformation.

Diagnostic Investigations

Biochemical Evaluation

• The primary and most sensitive diagnostic test (approaching 100% sensitivity) is the measurement of fractionated free metanephrines (metanephrine and normetanephrine) in the plasma or a 24-hour urine collection.
• An elevation of metanephrines greater than four times the upper limit of normal provides almost a 100% probability of a catecholamine-secreting tumor.
• Medications known to interfere with metanephrine assays, such as acetaminophen, tricyclic antidepressants, phenoxybenzamine, and over-the-counter decongestants, must be discontinued prior to testing.
• Testing for vanillylmandelic acid (VMA) and homovanillic acid (HVA) is no longer recommended for diagnosing pheochromocytoma, though it remains critical for neuroblastoma.
• In patients with known SDHx mutations, the measurement of dopamine and its metabolite methoxytyramine is advised, as these tumors may exclusively secrete dopamine.
• Serum chromogranin A is a major secretory protein from chromaffin granules that can serve as a supplementary tumor marker, often correlating with tumor size and malignant potential.

Anatomic Imaging

• Following biochemical confirmation, cross-sectional anatomic imaging with Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) of the abdomen and pelvis is required to localize the tumor.
• If abdominal imaging is negative, the imaging field should be expanded to include the neck and chest to locate extra-adrenal paragangliomas.
• On MRI, pheochromocytomas characteristically exhibit a marked hyperintense appearance on T2-weighted images, frequently referred to as the "lightbulb sign".
• These tumors are highly vascular and vigorously enhance with contrast; they commonly display internal areas of necrosis, cystic changes, or hemorrhage.

Functional and Nuclear Imaging

• Functional imaging is critical for confirming the diagnosis, evaluating for multifocal disease, and ruling out metastatic spread, especially in patients with high-risk genetic backgrounds (e.g., SDHB mutations).
• 68Ga-DOTATATE PET/CT: This is currently the functional imaging modality of choice due to its superior sensitivity and high specificity for the somatostatin receptors that are abundantly expressed on pheochromocytomas and paragangliomas.
• 123I-MIBG Scintigraphy: Metaiodobenzylguanidine (MIBG) is a norepinephrine analog that is actively taken up by chromaffin tissue; it remains a useful tool for localizing tumors and determining eligibility for targeted 131I-MIBG radiotherapy, though its sensitivity is lower than DOTATATE PET.
• 18F-FDG PET/CT: Fluorodeoxyglucose PET imaging is highly sensitive for rapidly metabolizing tumors and is particularly useful for detecting metastatic disease.

Genetic Testing

• Because up to 80% of pediatric cases have an underlying hereditary syndrome, formal genetic counseling and comprehensive genetic testing (often utilizing next-generation sequencing targeted gene panels) are mandatory for every child diagnosed with a pheochromocytoma or paraganglioma.

Management and Treatment

Preoperative Medical Blockade

• The cornerstone of management is meticulous preoperative medical preparation to normalize blood pressure, restore intravascular volume, and prevent life-threatening intraoperative catecholamine surges.
• Medical blockade must be initiated at least 10 to 14 days prior to any surgical intervention.
• Alpha-Adrenergic Blockade: This is the mandatory first step. Phenoxybenzamine, a noncompetitive alpha-1 and alpha-2 receptor antagonist, is commonly used (initial dose 0.2-0.25 mg/kg/day divided twice daily). Selective alpha-1 blockers like doxazosin or prazosin are excellent alternatives that may carry a lower risk of prolonged postoperative hypotension.
• Beta-Adrenergic Blockade: Beta-blockers (e.g., atenolol, metoprolol, propranolol) are added only after adequate alpha-blockade has been achieved to control tachycardia. Administering beta-blockers prior to alpha-blockers is strictly contraindicated, as the loss of beta-mediated vasodilation in the setting of unopposed alpha-mediated vasoconstriction can precipitate a catastrophic hypertensive crisis.
• Calcium Channel Blockers: Agents such as amlodipine or sustained-release nifedipine can be utilized as second-line or adjunctive therapy for blood pressure control.
• Catecholamine Synthesis Inhibition: Metyrosine, a competitive inhibitor of the rate-limiting enzyme tyrosine hydroxylase, can be added to the preoperative regimen to deplete catecholamine stores, though its use is sometimes limited by cost and central nervous system side effects.
• Volume Expansion: Patients undergo high oral salt loading and increased fluid intake in the final days before surgery; this expands the contracted vascular bed caused by chronic vasoconstriction and mitigates the profound hypotension that frequently follows tumor removal.

Surgical Management

• Surgical resection is the definitive treatment for pheochromocytomas and paragangliomas; preoperative needle biopsy is strictly contraindicated due to the risk of precipitating a fatal catecholamine crisis or causing tumor seeding.
• Laparoscopic adrenalectomy (via transperitoneal or retroperitoneal approach) is the procedure of choice for most intra-adrenal tumors.
• Open laparotomy is reserved for very large tumors, cases with suspected local invasion, or high concern for malignancy.
• Cortical-Sparing Surgery: In children with bilateral tumors or a known hereditary predisposition syndrome (e.g., MEN2, VHL), a cortical-sparing adrenalectomy is highly recommended. This approach preserves endogenous glucocorticoid and mineralocorticoid function, protecting the child from the severe lifelong risks associated with Addison disease, with local recurrence rates remaining acceptably low (less than 10%).
• The surgical and anesthesia teams must be highly experienced. Direct arterial blood pressure monitoring is required, and intravenous rapidly acting vasodilators (nitroprusside, phentolamine) and vasopressors (norepinephrine) must be immediately available to manage abrupt hemodynamic fluctuations during tumor manipulation and after venous ligation.

Postoperative Care and Prognosis

• Immediate postoperative monitoring in an intensive care setting is critical, focusing primarily on the risks of sudden hypotension (due to abrupt withdrawal of catecholamines into a dilated vascular bed) and rebound hypoglycemia (due to the sudden removal of catecholamine-mediated inhibition of insulin release).
• The overall long-term prognosis for pediatric patients with benign tumors is excellent, provided they survive the perioperative period without incident.
• Malignancy in pheochromocytoma/paraganglioma is definitively diagnosed only by the presence of metastatic spread to tissues devoid of normal chromaffin tissue, such as lymph nodes, liver, lungs, or bone.
• Because children possess a high risk (up to 50% over their lifetime) of developing metachronous primary tumors, delayed local recurrence, or late metastatic disease, they require stringent lifelong surveillance.
• Long-term follow-up protocols involve annual physical examinations, blood pressure monitoring, annual biochemical screening (plasma or urine metanephrines), and periodic whole-body MRI, particularly tailored to the specific genetic mutation identified.